TY - JOUR
T1 - Percutaneous Radiofrequency Ablation of Lung Cancer Presenting as Ground-Glass Opacity
AU - Iguchi, Toshihiro
AU - Hiraki, Takao
AU - Gobara, Hideo
AU - Fujiwara, Hiroyasu
AU - Matsui, Yusuke
AU - Sou, Junichi
AU - Toyooka, Shinichi
AU - Kiura, Katsuyuki
AU - Kanazawa, Susumu
N1 - Publisher Copyright:
© 2014, Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2015/4
Y1 - 2015/4
N2 - Purpose: We retrospectively evaluated the outcomes of lung cancer patients presenting with ground-glass opacity (GGO) who received radiofrequency ablation (RFA).Methods: Sixteen patients (5 men and 11 women; mean age, 72.6 years) with 17 lung cancer lesions showing GGO (mean long axis diameter, 1.6 cm) underwent a total of 20 percutaneous computed tomography (CT) fluoroscopy-guided RFA sessions, including three repeated sessions for local progression. Lung cancer with GGO was defined as a histologically confirmed malignant pulmonary lesion with a GGO component accounting for >50 % of the lesion on high-resolution CT. Procedure outcomes were evaluated.Results: There were no major complications. Pneumothorax occurred in 15 of 20 treatment sessions: 14 were asymptomatic, and 1 required chest tube placement but resolved satisfactorily within 48 h. Minor pulmonary hemorrhage occurred in two and mild pneumonitis in one. The median tumor follow-up period was 61.5 (range 6.1–96.6) months. The effectiveness rates of the primary and secondary techniques were 100 and 100 % at 1 year, 93.3 and 100 % at 2 years, and 78.3 and 92.3 % at 3 years, respectively. The median patient follow-up period was 65.6 (range 6.1–96.6) months. One patient died owing to recurrent other cancer 11.7 months after RFA, whereas the other 15 remained alive. Overall survival and disease-specific survival rates were 93.3 and 100 % at 1 year and 93.3 and 100 % at 5 years, respectively.Conclusions: RFA for lung cancer with GGO was safe and effective, and resulted in promising survival rates.
AB - Purpose: We retrospectively evaluated the outcomes of lung cancer patients presenting with ground-glass opacity (GGO) who received radiofrequency ablation (RFA).Methods: Sixteen patients (5 men and 11 women; mean age, 72.6 years) with 17 lung cancer lesions showing GGO (mean long axis diameter, 1.6 cm) underwent a total of 20 percutaneous computed tomography (CT) fluoroscopy-guided RFA sessions, including three repeated sessions for local progression. Lung cancer with GGO was defined as a histologically confirmed malignant pulmonary lesion with a GGO component accounting for >50 % of the lesion on high-resolution CT. Procedure outcomes were evaluated.Results: There were no major complications. Pneumothorax occurred in 15 of 20 treatment sessions: 14 were asymptomatic, and 1 required chest tube placement but resolved satisfactorily within 48 h. Minor pulmonary hemorrhage occurred in two and mild pneumonitis in one. The median tumor follow-up period was 61.5 (range 6.1–96.6) months. The effectiveness rates of the primary and secondary techniques were 100 and 100 % at 1 year, 93.3 and 100 % at 2 years, and 78.3 and 92.3 % at 3 years, respectively. The median patient follow-up period was 65.6 (range 6.1–96.6) months. One patient died owing to recurrent other cancer 11.7 months after RFA, whereas the other 15 remained alive. Overall survival and disease-specific survival rates were 93.3 and 100 % at 1 year and 93.3 and 100 % at 5 years, respectively.Conclusions: RFA for lung cancer with GGO was safe and effective, and resulted in promising survival rates.
KW - Cancer
KW - Lung
KW - Radiofrequency ablation
UR - http://www.scopus.com/inward/record.url?scp=84939876986&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939876986&partnerID=8YFLogxK
U2 - 10.1007/s00270-014-0926-x
DO - 10.1007/s00270-014-0926-x
M3 - Article
C2 - 24938905
AN - SCOPUS:84939876986
SN - 7415-5101
VL - 38
SP - 409
EP - 415
JO - Cardiovascular Radiology
JF - Cardiovascular Radiology
IS - 2
ER -